French biotechnology company Medesis Pharma has asked the Defense Innovation Agency for funds to accelerate the development of three drugs for mass use in different scenarios of nuclear contamination of the population.
The three experimental drugs are designed to treat large populations that have been contaminated or irradiated as a result of either civil nuclear accidents, warfare or terrorist acts.
The need to accelerate the work on drugs of this type results both from the tragic situation in Ukraine and its geopolitical consequences, as well as from the latest decisions of many countries to maintain the development of nuclear energy. The drugs are dev...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
